| Description | DCDC1 Human Pre-designed siRNA Set A contains three designed siRNAs for DCDC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DCDC1 siRNA-1: 5 nmol (HPLC) DCDC1 siRNA-2: 5 nmol (HPLC) DCDC1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:DCDC1 Human Pre-designed siRNA Set A contains three designed siRNAs for DCDC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DCDC1 siRNA-1: 5 nmol (HPLC) DCDC1 siRNA-2: 5 nmol (HPLC) DCDC1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Usually used industrially for the resolution of chiral compounds and the transesterification production of biodiesel | Purity:>90%, by SDS-PAGE visualized with Coomassie® Blue Staining.This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport | Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases... Read More |